179 related articles for article (PubMed ID: 21039543)
1. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
[TBL] [Abstract][Full Text] [Related]
2. Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability.
Flaten GE; Skar M; Luthman K; Brandl M
Eur J Pharm Sci; 2007 Mar; 30(3-4):324-32. PubMed ID: 17204409
[TBL] [Abstract][Full Text] [Related]
3. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants.
Fischer SM; Flaten GE; Hagesæther E; Fricker G; Brandl M
J Pharm Pharmacol; 2011 Aug; 63(8):1022-30. PubMed ID: 21718285
[TBL] [Abstract][Full Text] [Related]
4. Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes.
Flaten GE; Bunjes H; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jul; 28(4):336-43. PubMed ID: 16697561
[TBL] [Abstract][Full Text] [Related]
5. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
6. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
7. Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay.
Fischer SM; Buckley ST; Kirchmeyer W; Fricker G; Brandl M
Int J Pharm; 2012 Jan; 422(1-2):52-8. PubMed ID: 22027395
[TBL] [Abstract][Full Text] [Related]
8. Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability.
Flaten GE; Luthman K; Vasskog T; Brandl M
Eur J Pharm Sci; 2008 Jul; 34(2-3):173-80. PubMed ID: 18499410
[TBL] [Abstract][Full Text] [Related]
9. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
10. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies.
Kleberg K; Jacobsen J; Müllertz A
J Pharm Pharmacol; 2010 Nov; 62(11):1656-68. PubMed ID: 21039549
[TBL] [Abstract][Full Text] [Related]
11. Investigation of vesicle electrokinetic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drug candidates.
Pascoe RJ; Masucci JA; Foley JP
Electrophoresis; 2006 Feb; 27(4):793-804. PubMed ID: 16411277
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of a novel phospholipid-based depot injectable technology for poorly water-soluble drugs.
Tiemessen H; van Hoogevest P; Leigh ML
Eur J Pharm Biopharm; 2004 Nov; 58(3):587-93. PubMed ID: 15451533
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
14. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material.
Dai WG; Dong LC; Li S; Pollock-Dove C; Chen J; Mansky P; Eichenbaum G
Int J Pharm; 2007 May; 336(1):1-11. PubMed ID: 17178444
[TBL] [Abstract][Full Text] [Related]
15. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
16. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
Vasconcelos T; Sarmento B; Costa P
Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
[TBL] [Abstract][Full Text] [Related]
17. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.
Tho I; Liepold B; Rosenberg J; Maegerlein M; Brandl M; Fricker G
Eur J Pharm Sci; 2010 Apr; 40(1):25-32. PubMed ID: 20172027
[TBL] [Abstract][Full Text] [Related]
18. Amorphous drug dispersions with mono- and diacyl lecithin: On molecular categorization of their feasibility and UV dissolution imaging.
Gautschi N; Van Hoogevest P; Kuentz M
Int J Pharm; 2015 Aug; 491(1-2):218-30. PubMed ID: 26129840
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical properties of water and its effect on drug delivery. A commentary.
Loftsson T; Brewster ME
Int J Pharm; 2008 Apr; 354(1-2):248-54. PubMed ID: 17920796
[TBL] [Abstract][Full Text] [Related]
20. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations.
Al-Hamidi H; Edwards AA; Mohammad MA; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Mar; 76(1):170-8. PubMed ID: 19945828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
